Thursday - March 28, 2024
UniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for Treatment of Huntington's Disease
June 20, 2020
NEW YORK, June 20 -- The Huntington's Disease Society of America issued the following news:

UniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease have been treated. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States, with now one . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products